Form 4: Allogene Therapeutics Director Stephen Mayo Acquires Stock Options

Director Stephen Mayo acquired stock options for Allogene Therapeutics, Inc. on June 5, 2024.

Summary

• On June 5, 2024, Stephen Mayo, a director of Allogene Therapeutics, Inc., acquired stock options.
• The stock options grant him the right to buy 191,082 shares of common stock at an exercise price of $2.44.
• The options vest in 12 equal monthly installments and expire on June 5, 2034.
• Following the transaction, Mayo directly owns 191,082 derivative securities.

Sentiment

Score: 5

Explanation: This Form 4 filing is a routine disclosure of stock option grants to a company director. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard compensation practices.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard disclosure related to insider transactions, common in the biopharmaceutical industry where stock options are frequently used as part of executive compensation packages.

Comparison to Industry Standards

• Stock option grants are a common component of compensation packages for directors and executives in publicly traded companies, particularly in the biotechnology sector.
• The vesting schedule of 12 equal monthly installments is a fairly standard practice.
• Comparing the size of the grant to those of directors at comparable companies (e.g., CRISPR Therapeutics, Beam Therapeutics) would provide further context on its significance.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.

Key Dates